Leptomeningeal metastases: a RANO proposal for response criteria

Leptomeningeal metastases (LM) currently lack standardization with respect to response assessment. A Response Assessment in Neuro-Oncology (RANO) working group with expertise in LM developed a consensus proposal for evaluating patients treated for this disease. Three basic elements in assessing response in LM are proposed: a standardized neurological examination, cerebral spinal fluid (CSF) cytology or flow cytometry, and radiographic evaluation. The group recommends that all patients enrolling in clinical trials undergo CSF analysis (cytology in all cancers; flow cytometry in hematologic cancers), complete contrast-enhanced neuraxis MRI, and in instances of planned intra-CSF therapy, radioisotope CSF flow studies. In conjunction with the RANO Neurological Assessment working group, a standardized instrument was created for assessing the neurological exam in patients with LM. Considering that most lesions in LM are nonmeasurable and that assessment of neuroimaging in LM is subjective, neuroimaging is graded as stable, progressive, or improved using a novel radiological LM response scorecard. Radiographic disease progression in isolation (ie, negative CSF cytology/flow cytometry and stable neurological assessment) would be defined as LM disease progression. The RANO LM working group has proposed a method of response evaluation for patients with LM that will require further testing, validation, and likely refinement with use.

[1]  M. Martínez-García,et al.  Diagnostic and prognostic significance of flow cytometry immunophenotyping in patients with leptomeningeal carcinomatosis , 2015, Clinical & Experimental Metastasis.

[2]  P. Wen,et al.  Leptomeningeal metastasis: a Response Assessment in Neuro-Oncology critical review of endpoints and response criteria of published randomized clinical trials. , 2014, Neuro-oncology.

[3]  D. Osoba,et al.  A global analysis of multitrial data investigating quality of life and symptoms as prognostic factors for survival in different tumor sites , 2014, Cancer.

[4]  Maria Werner-Wasik,et al.  Net clinical benefit analysis of radiation therapy oncology group 0525: a phase III trial comparing conventional adjuvant temozolomide with dose-intensive temozolomide in patients with newly diagnosed glioblastoma. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  Susan M. Chang,et al.  Challenges relating to solid tumour brain metastases in clinical trials, part 2: neurocognitive, neurological, and quality-of-life outcomes. A report from the RANO group. , 2013, The Lancet. Oncology.

[6]  A. Sinnarajah,et al.  Managing brain metastases patientswith and without radiotherapy: initial lessonsfrom a team-based consult service through a multidisciplinary integrated palliative oncology clinic , 2013, Supportive Care in Cancer.

[7]  S. Aamdal,et al.  Role functioning before start of adjuvant treatment was an independent prognostic factor for survival and time to failure. A report from the Nordic adjuvant interferon trial for patients with high-risk melanoma , 2013, Acta oncologica.

[8]  L. Deangelis,et al.  Rare cell capture technology for the diagnosis of leptomeningeal metastasis in solid tumors , 2013, Neurology.

[9]  M. De Carvalho Bittencourt,et al.  Detection and quantification of CSF malignant cells by the CellSearch® technology in patients with melanoma leptomeningeal metastasis , 2013, Medical Oncology.

[10]  M. Chamberlain.  Comprehensive neuraxis imaging in leptomeningeal metastasis: a retrospective case series. , 2013, CNS oncology.

[11]  J. Bonneterre,et al.  Development of a new method for identification and quantification in cerebrospinal fluid of malignant cells from breast carcinoma leptomeningeal metastasis , 2012, BMC Clinical Pathology.

[12]  V. Pavone,et al.  Final results of a multicenter trial addressing role of CSF flow cytometric analysis in NHL patients at high risk for CNS dissemination. , 2012, Blood.

[13]  H. Brambs,et al.  Use of magnetic resonance imaging to detect neoplastic meningitis: limited use in leukemia and lymphoma but convincing results in solid tumors. , 2012, European journal of radiology.

[14]  W. El-Deiry,et al.  Identification and enumeration of circulating tumor cells in the cerebrospinal fluid of breast cancer patients with central nervous system metastases , 2011, Oncotarget.

[15]  J. Gratama,et al.  Flow cytometric characterization of cerebrospinal fluid cells , 2011, Cytometry. Part B, Clinical cytometry.

[16]  J. Connor,et al.  Detection of cancer cells in the cerebrospinal fluid: current methods and future directions , 2011, Fluids and Barriers of the CNS.

[17]  A. Salar,et al.  Clinical significance of occult cerebrospinal fluid involvement assessed by flow cytometry in non‐Hodgkin’s lymphoma patients at high risk of central nervous system disease in the rituximab era , 2010, European journal of haematology.

[18]  L. Jacks,et al.  Leptomeningeal metastases in the MRI era , 2010, Neurology.

[19]  T. Hirai,et al.  Comparison of the Added Value of Contrast-Enhanced 3D Fluid-Attenuated Inversion Recovery and Magnetization-Prepared Rapid Acquisition of Gradient Echo Sequences in Relation to Conventional Postcontrast T1-Weighted Images for the Evaluation of Leptomeningeal Diseases at 3T , 2010, American Journal of Neuroradiology.

[20]  M. Groves,et al.  Known and emerging biomarkers of leptomeningeal metastasis and its response to treatment. , 2010, Future oncology.

[21]  W. Wilson,et al.  Diagnostic tools for neoplastic meningitis: detecting disease, identifying patient risk, and determining benefit of treatment. , 2009, Seminars in oncology.

[22]  J. Briones,et al.  Identification of leptomeningeal disease in aggressive B-cell non-Hodgkin's lymphoma: improved sensitivity of flow cytometry. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  M. Gilbert,et al.  Biomarkers of disease: cerebrospinal fluid vascular endothelial growth factor (VEGF) and stromal cell derived factor (SDF)-1 levels in patients with neoplastic meningitis (NM) due to breast cancer, lung cancer and melanoma , 2009, Journal of Neuro-Oncology.

[24]  A. Silvani,et al.  Intrathecal synthesis of tumor markers is a highly sensitive test in the diagnosis of leptomeningeal metastasis from solid cancers , 2009, Clinical chemistry and laboratory medicine.

[25]  W. Wilson,et al.  Flow Cytometric Immunophenotyping of Cerebrospinal Fluid , 2008, Current protocols in cytometry.

[26]  M. Gilbert,et al.  A multicenter phase II trial of intrathecal topotecan in patients with meningeal malignancies. , 2008, Neuro-oncology.

[27]  M. J. van den Bent,et al.  CSF flow cytometry greatly improves diagnostic accuracy in CNS hematologic malignancies , 2007, Neurology.

[28]  J. Smirniotopoulos,et al.  Patterns of contrast enhancement in the brain and meninges. , 2007, Radiographics : a review publication of the Radiological Society of North America, Inc.

[29]  B. Spengler,et al.  Identification of leptomeningeal metastasis‐related proteins in cerebrospinal fluid of patients with breast cancer by a combination of MALDI‐TOF, MALDI‐FTICR and nanoLC‐FTICR MS , 2007, Proteomics.

[30]  M. Glantz,et al.  A randomized phase III/IV study to determine benefit and safety of cytarabine liposome injection for treatment of neoplastic meningitis. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  H. Nückel,et al.  Detection of malignant haematopoietic cells in the cerebrospinal fluid by conventional cytology and flow cytometry. , 2006, Clinical and laboratory haematology.

[32]  M. Bahr,et al.  Automated cerebrospinal fluid cytology: limitations and reasonable applications. , 2005, Analytical and quantitative cytology and histology.

[33]  W. Wilson,et al.  High incidence of occult leptomeningeal disease detected by flow cytometry in newly diagnosed aggressive B-cell lymphomas at risk for central nervous system involvement: the role of flow cytometry versus cytology. , 2005, Blood.

[34]  W. Morice,et al.  Clinical significance of monoclonal B cells in cerebrospinal fluid , 2005, Cytometry. Part B, Clinical cytometry.

[35]  L. Sandhaus.  Automated flow cytometric analysis of blood cells in cerebrospinal fluid. , 2005, American journal of clinical pathology.

[36]  M. Chamberlain.  Comparative spine imaging in leptomeningeal metastases , 2005, Journal of Neuro-Oncology.

[37]  A. Hart,et al.  The relevance of intraventricular chemotherapy for leptomeningeal metastasis in breast cancer: a randomised study. , 2004, European journal of cancer.

[38]  K. Lackner,et al.  Automated flow cytometric analysis of blood cells in cerebrospinal fluid: analytic performance. , 2004, American journal of clinical pathology.

[39]  T. Siegal.  Leptomeningeal metastases: Rationale for systemic chemotherapy or what is the role of intra-CSF-chemotherapy? , 1998, Journal of Neuro-Oncology.

[40]  M. Chamberlain.  Radioisotope CSF flow studies in leptomeningeal metastases , 1998, Journal of Neuro-Oncology.

[41]  N. Leeds,et al.  MR imaging of leptomeningeal metastases: comparison of three sequences. , 2002, AJNR. American journal of neuroradiology.

[42]  P. J. Hoopes,et al.  Visualization of intravenously administered contrast material in the CSF on fluid-attenuated inversion-recovery MR images: an in vitro and animal-model investigation. , 2000, AJNR. American journal of neuroradiology.

[43]  L. Recht,et al.  A randomized controlled trial comparing intrathecal sustained-release cytarabine (DepoCyt) to intrathecal methotrexate in patients with neoplastic meningitis from solid tumors. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[44]  S. Phuphanich,et al.  Randomized trial of a slow-release versus a standard formulation of cytarabine for the intrathecal treatment of lymphomatous meningitis. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[45]  T. Merchant,et al.  Comparison of lumbar and shunt cerebrospinal fluid specimens for cytologic detection of leptomeningeal disease in pediatric patients with brain tumors. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[46]  M. Lowe,et al.  Brain: gadolinium-enhanced fast fluid-attenuated inversion-recovery MR imaging. , 1999, Radiology.

[47]  K. Jaeckle,et al.  111Indium-diethylenetriamine pentaacetic acid CSF flow studies predict distribution of intrathecally administered chemotherapy and outcome in patients with leptomeningeal metastases. , 1999, Neurology.

[48]  M. Chamberlain,et al.  Cytologically negative carcinomatous meningitis: Usefulness of CSF biochemical markers , 1998, Neurology.

[49]  B. Cole,et al.  Cerebrospinal fluid cytology in patients with cancer , 1998, Cancer.

[50]  L. Deangelis,et al.  111Indium-diethylenetriamine pentaacetic acid cerebrospinal fluid flow studies predict distribution of intrathecally administered chemotherapy and outcome in patients with leptomeningeal metastases. , 1998, Neurology.

[51]  M. Chamberlain,et al.  Prognostic significance of coexistent bulky metastatic central nervous system disease in patients with leptomeningeal metastases. , 1997, Archives of neurology.

[52]  M. Chamberlain,et al.  Prognostic significance of sup 111 Indium-DTPA CSF flow studies in leptomeningeal metastases , 1996, Neurology.

[53]  G. Krol,et al.  Neuroimaging and cerebrospinal fluid cytology in the diagnosis of leptomeningeal metastasis , 1995, Annals of neurology.

[54]  D. Yousem,et al.  Frequency of unexplained meningeal enhancement in the brain after lumbar puncture. , 1994, AJNR. American journal of neuroradiology.

[55]  P. Faustmann,et al.  A standardized protocol for flow cytometric analysis of cells isolated from cerebrospinal fluid , 1994, Journal of the Neurological Sciences.

[56]  D. Ettinger,et al.  Randomized prospective comparison of intraventricular methotrexate and thiotepa in patients with previously untreated neoplastic meningitis. Eastern Cooperative Oncology Group. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[57]  J. Boyett,et al.  Comparison of cisternal and lumbar CSF examination in leptomeningeal metastasis , 1992, Neurology.

[58]  R. Hitchins,et al.  A prospective randomized trial of single-agent versus combination chemotherapy in meningeal carcinomatosis. , 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[59]  D. Trump,et al.  Cerebrospinal fluid flow abnormalities in patients with neoplastic meningitis. An evaluation using 111indium-DTPA ventriculography. , 1982, The American journal of medicine.

[60]  M. Melamed,et al.  Malignant cells in cerebrospinal fluid (CSF): The meaning of a positive CSF cytology , 2011, Neurology.

[61]  W. Shapiro,et al.  Methotrexate: distribution in cerebrospinal fluid after intravenous, ventricular and lumbar injections. , 1975, The New England journal of medicine.